Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pal Miheller

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Inflammatory Bowel Diseases|October 31, 2008
Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohortPeter Laszlo Lakatos, Istvan Altorjay, Tamas Szamosi, et al.
Inflammatory Bowel Diseases|April 10, 2007
Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patientsMaria Papp, Istvan Altorjay, Gary L Norman, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 4, 2021
Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab - A prospective, multicenter cohort from HungaryLorant Gonczi, Kata Szanto, Klaudia Farkas, et al.
Scientific Reports|June 28, 2024
Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn's disease patients over three yearsLaszlo J Barkai, Lorant Gonczi, Fruzsina Balogh, et al.
Inflammatory Bowel Diseases|September 19, 2017
Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide CohortLorant Gonczi, Krisztina B Gecse, Zsuzsanna Vegh, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Inflammatory Bowel Diseases|October 31, 2008
Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohortPeter Laszlo Lakatos, Istvan Altorjay, Tamas Szamosi, et al.
Inflammatory Bowel Diseases|April 10, 2007
Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patientsMaria Papp, Istvan Altorjay, Gary L Norman, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 4, 2021
Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab - A prospective, multicenter cohort from HungaryLorant Gonczi, Kata Szanto, Klaudia Farkas, et al.
Scientific Reports|June 28, 2024
Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn's disease patients over three yearsLaszlo J Barkai, Lorant Gonczi, Fruzsina Balogh, et al.
Inflammatory Bowel Diseases|September 19, 2017
Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide CohortLorant Gonczi, Krisztina B Gecse, Zsuzsanna Vegh, et al.
Pageof 3